NovaBridge Biosciences
NBPInstitutional ownership · Q3 2026
47 institutional managers reported holding 22,775,245 shares worth $31,086,637 on Form 13F for Q3 2026, against 49 in Q2 2026. Share positions on CUSIP 44975P103 only; option legs and principal-amount lines are not counted.
Top 25 institutional holders · Q3 2026
| # | Manager | Shares | Value | % of portfolio | Change | Position page |
|---|---|---|---|---|---|---|
| 1 | HHLR ADVISORS LTD | 5,980,568 | $8.2M | 0.53% | — | Position |
| 2 | MORGAN STANLEY | 3,471,552 | $4.7M | < 0.01% | -181.7K | Position |
| 3 | AIHC Capital Management Ltd | 2,878,033 | $3.9M | 3.61% | — | Position |
| 4 | CITADEL ADVISORS LLC | 1,381,516 | $1.9M | < 0.01% | +758.7K | Position |
| 5 | Candriam S C A | 1,132,563 | $1.6M | < 0.01% | — | Position |
| 6 | ADAGE CAPITAL PARTNERS GP L L C | 1,000,000 | $1.4M | < 0.01% | — | Position |
| 7 | TWO SIGMA INVESTMENTS LP | 874,250 | $1.2M | < 0.01% | +22.9K | Position |
| 8 | BlackRock Inc | 749,282 | $1.0M | < 0.01% | +63.1K | Position |
| 9 | MARSHALL WACE LLP | 727,345 | $989.2K | < 0.01% | -504.6K | Position |
| 10 | UBS Group AG | 689,762 | $941.5K | < 0.01% | +388.0K | Position |
| 11 | Exome Asset Management LLC | 576,960 | $787.6K | 0.51% | — | Position |
| 12 | DIADEMA PARTNERS LP | 500,000 | $682.5K | 0.09% | New | Position |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 485,191 | $662.3K | < 0.01% | -273.0K | Position |
| 14 | Woodline Partners LP | 350,000 | $477.8K | < 0.01% | — | Position |
| 15 | Fiera Capital Corp | 315,681 | $430.9K | < 0.01% | — | Position |
| 16 | STATE STREET CORPORATION | 312,640 | $426.8K | < 0.01% | -47.7K | Position |
| 17 | XTX Topco Ltd | 159,492 | $217.7K | < 0.01% | New | Position |
| 18 | ALPS ADVISORS INC | 150,167 | $205.0K | < 0.01% | +33.1K | Position |
| 19 | JANE STREET GROUP LLC | 145,666 | $198.8K | < 0.01% | +127.3K | Position |
| 20 | Persistent Asset Partners Ltd | 126,943 | $173.3K | 0.05% | New | Position |
| 21 | The Goldman Sachs Group Inc | 124,643 | $170.1K | < 0.01% | -36.7K | Position |
| 22 | Quadrature Capital Ltd | 109,026 | $148.8K | < 0.01% | New | Position |
| 23 | ACADIAN ASSET MANAGEMENT LLC | 98,344 | $131.0K | < 0.01% | New | Position |
| 24 | Invesco Ltd | 73,731 | $100.6K | < 0.01% | +10.8K | Position |
| 25 | HRT FINANCIAL LP | 59,010 | $80.0K | < 0.01% | New | Position |
Values as reported on each manager's Q3 2026 Form 13F. Change is in shares against the manager's prior-quarter filing.
13F holders by quarter
| Quarter | Holders | Shares | Value |
|---|---|---|---|
| Q3 2026 | 47 -2 | 22.8M | $31.1M |
| Q2 2026 | 49 +1 | 24.7M | $48.1M |
| Q1 2026 | 48 -8 | 29.3M | $72.1M |
| Q4 2025 | 56 +14 | 33.2M | $132.1M |
| Q3 2025 | 42 +10 | 29.7M | $112.3M |
| Q2 2025 | 32 +3 | 9.4M | $22.7M |
| Q1 2025 | 29 +1 | 9.0M | $7.4M |
| Q4 2024 | 28 | 11.9M | $10.1M |
| Q3 2024 | 28 -10 | 14.2M | $17.6M |
| Q2 2024 | 38 -1 | 15.1M | $25.3M |
| Q1 2024 | 39 -5 | 12.2M | $22.7M |
| Q4 2023 | 44 -3 | 12.3M | $23.5M |
| Q3 2023 | 47 -1 | 19.4M | $33.4M |
| Q2 2023 | 48 -5 | 18.7M | $55.9M |
| Q1 2023 | 53 -15 | 20.7M | $71.6M |
| Q4 2022 | 68 -6 | 24.9M | $103.9M |
| Q3 2022 | 74 -20 | 30.8M | $123.3M |
| Q2 2022 | 94 -21 | 38.2M | $430.9M |
| Q1 2022 | 115 -12 | 40.3M | $657.1M |
| Q4 2021 | 127 | 38.9M | $1.8B |
Q4 2021–Q3 2026, as reported on Form 13F. Earlier quarters are in the ownership explorer below.
Across other SEC filings
Fund holders · N-PORT
14 funds| Fund | Value | % of fund | As of |
|---|---|---|---|
| iShares Biotechnology ETF IBB | $1.2M | 0.01% | Jun 2026 |
| State Street(R) SPDR(R) Portfolio Emerging Markets ETF SPEM | $580.8K | < 0.01% | Jun 2026 |
| ALPS Medical Breakthroughs ETF SBIO | $259.9K | 0.11% | Aug 2026 |
| Invesco NASDAQ Future Gen 200 ETF QQQS | $110.5K | 0.49% | Aug 2026 |
| State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF EWX | $94.2K | 0.01% | Jun 2026 |
| Fidelity Nasdaq Composite Index Fund | $80.3K | < 0.01% | Aug 2026 |
| World ex U.S. Core Equity Portfolio | $42.1K | < 0.01% | Jul 2026 |
| EMERGING MARKETS CORE EQUITY 2 PORTFOLIO | $32.1K | < 0.01% | Jul 2026 |
| State Street(R) SPDR(R) S&P(R) China ETF GXC | $27.7K | < 0.01% | Jun 2026 |
| Emerging Markets Social Core Equity Portfolio | $24.2K | < 0.01% | Jul 2026 |
14 funds reported holding $2,449,779 in total on their latest public Form N-PORT reports, the most recent dated August 2026.
5%+ holders · 13D/G
3 filers| Filer | % of class | Filed |
|---|---|---|
| HHLR ADVISORS LTD 13D | 4.9% | 2026-11-06 |
| CBC Investment I-Mab Limited 13D | 11.5% | 2026-02-03 |
| Everest Medicines Limited 13D | 16.1% | 2025-08-05 |
Latest Schedule 13D or 13G from each filer naming this CUSIP; stakes a filer has reported closed are left out.
Insiders · Form 4
- Ian Ying Woo 2026-10-19 Exercise
- Phillip Andrew Dennis 2026-09-21 Sell
- Sean Wuxiong Cao 2026-09-11 Sell
- Sean Wuxiong Cao 2026-09-08 Exercise
- Cong Claire Xu 2026-09-01 Sell
Ownership explorer
Security Details
| CUSIP | 44975P103 |
|---|---|
| FIGI | BBG00QQ8DG97 |
| Symbol | NBP |
| Type | Adr |
| Class | SPONSORED ADS as filed on 13F |
| Exchange | Nasdaq |
| Company | NovaBridge Biosciences |
Identifier History
| Type | Value | From | To |
|---|---|---|---|
| FIGI | BBG00QQ8DG97 | 2026-02-07 | Current |
| CUSIP | 44975P103 | 2020-03-31 | Current |
Listing History
| Symbol | Exchange | From | To |
|---|---|---|---|
| NBP | Nasdaq | 2025-10-31 | Current |
| IMAB | Nasdaq | 2020-05-04 | 2026-07-18 |